Suchergebnisse - "Obermannova, R"

PubPharm (26)

1

Reply to the Letter to the Editor 'Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to "Oesophageal cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up")' by Cellini et al

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Obermannová, R. | Smyth, E. | ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

CommentOn: Ann Oncol. 2022 Oct;33(10):992-1004. - PMID 35914638

2

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

enthalten in: ESMO open | 2023

von Ducreux, M. | Abou-Alfa, G. | Bekaii-Saab, T. | +28

3

The effect of immunotherapy in a young patient with mismatch repair-deficient rectal cancer - a case report

enthalten in: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti | 2023

von Sokop, T. | Obermannová, R.

4

Oesophageal cancer : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Obermannová, R. | Alsina, M. | Cervantes, A. | +7

CommentIn: Ann Oncol. 2023 Jun;34(6):553-554. - PMID 36965575

5

Isatuximab plus atezolizumab in patients with advanced solid tumors : results from a phase I/II, open-label, multicenter study

enthalten in: ESMO open | 2022

von Simonelli, M. | Garralda, E. | Eskens, F. | +29

6

Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2022

von Hacker, U. | Hasenclever, D. | Baber, R. | +6

CommentIn: Ann Oncol. 2022 Jul;33(7):669-671. - PMID 35430371

7

ESMO Congress 2021 : highlights from the EORTC gastrointestinal tract cancer group's perspective

enthalten in: ESMO open | 2022

von Koessler, T. | Alsina, M. | Arnold, D. | +13

8

The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review

enthalten in: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti | 2021

von Zemanová, M. | Obermannová, R. | Haruštiak, T.

9

Managing cancer patients during the COVID-19 pandemic : an ESMO multidisciplinary expert consensus

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Curigliano, G. | Banerjee, S. | Cervantes, A. | +76

10

Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Yoshino, T. | Portnoy, D. | Obermannová, R. | +19